Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17873
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSherry, Norelle L-
dc.contributor.authorBaines, Sarah L-
dc.contributor.authorHowden, Benjamin P-
dc.date2018-02-27-
dc.date.accessioned2018-06-19T06:23:58Z-
dc.date.available2018-06-19T06:23:58Z-
dc.date.issued2018-07-
dc.identifier.citationInternational journal of antimicrobial agents 2018; 52(1): 82-85-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/17873-
dc.description.abstractAvibactam (AVI) is a novel β-lactamase inhibitor active against class A, class C and some class D β-lactamases. In combination with ceftazidime, AVI may be useful for the treatment of infections due to Gram-negative bacteria producing carbapenemases from these classes; however, susceptibility data for some of the less common carbapenemases are limited. To assess the in vitro activity of ceftazidime/avibactam (CZA), a panel of 50 diverse carbapenemase-producing Gram-negative bacteria collected from clinical samples in Victoria, Australia, containing KPC, GES, SME, OXA-23 and OXA-48-like carbapenemases were tested for susceptibility to CZA using the broth microdilution (BMD), Etest and disk diffusion methods. All isolates were susceptible to CZA. Etest correlated well with BMD, although Etest minimum inhibitory concentrations (MICs) were generally lower than BMD. Disk diffusion correlated moderately well with BMD, with two interpretive errors. This study confirms phenotypic CZA susceptibility in the carbapenemase groups tested, including the less common OXA-23-producing Escherichia coli, SME-producing Serratia marcescens and GES-5-producing Pseudomonas aeruginosa.-
dc.language.isoeng-
dc.subjectCarbapenemase-producing Gram-negatives-
dc.subjectCeftazidime/avibactam-
dc.subjectGES carbapenemase-
dc.subjectKlebsiella pneumoniae carbapenemase (KPC)-
dc.subjectOXA carbapenemase-
dc.subjectβ-Lactamase-
dc.titleCeftazidime/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia.-
dc.typeJournal Article-
dc.identifier.journaltitleInternational journal of antimicrobial agents-
dc.identifier.affiliationAntimicrobial Reference and Research Unit, Microbiological Diagnostic Unit-Public Health Laboratory, Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Victoria, Australia-
dc.identifier.affiliationDepartment of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Victoria, Australia-
dc.identifier.affiliationDepartment of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1016/j.ijantimicag.2018.02.017-
dc.identifier.orcid0000-0002-7789-8360en
dc.identifier.orcid0000-0003-0237-1473en
dc.identifier.pubmedid29499316-
dc.type.austinJournal Article-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMicrobiology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Feb 7, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.